BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 23736274)

  • 1. Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff?
    Gazzaniga P; Raimondi C; Gradilone A; Biondi Zoccai G; Nicolazzo C; Gandini O; Longo F; Tomao S; Lo Russo G; Seminara P; Vincenzi B; Chimenti I; Cristofanilli M; Frati L; Cortesi E
    J Cancer Res Clin Oncol; 2013 Aug; 139(8):1411-6. PubMed ID: 23736274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer.
    Cohen SJ; Punt CJ; Iannotti N; Saidman BH; Sabbath KD; Gabrail NY; Picus J; Morse MA; Mitchell E; Miller MC; Doyle GV; Tissing H; Terstappen LW; Meropol NJ
    Ann Oncol; 2009 Jul; 20(7):1223-9. PubMed ID: 19282466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
    Cohen SJ; Punt CJ; Iannotti N; Saidman BH; Sabbath KD; Gabrail NY; Picus J; Morse M; Mitchell E; Miller MC; Doyle GV; Tissing H; Terstappen LW; Meropol NJ
    J Clin Oncol; 2008 Jul; 26(19):3213-21. PubMed ID: 18591556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
    Barbazán J; Muinelo-Romay L; Vieito M; Candamio S; Díaz-López A; Cano A; Gómez-Tato A; Casares de Cal Mde L; Abal M; López-López R
    Int J Cancer; 2014 Dec; 135(11):2633-43. PubMed ID: 24752533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor cells as an independent prognostic factor in advanced colorectal cancer: a retrospective study in 121 patients.
    Wang L; Zhou S; Zhang W; Wang J; Wang M; Hu X; Liu F; Zhang Y; Jiang B; Yuan H
    Int J Colorectal Dis; 2019 Apr; 34(4):589-597. PubMed ID: 30627849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor cells count predicts survival in colorectal cancer patients.
    Romiti A; Raffa S; Di Rocco R; Roberto M; Milano A; Zullo A; Leone L; Ranieri D; Mazzetta F; Medda E; Sarcina I; Barucca V; D'Antonio C; Durante V; Ferri M; Torrisi MR; Marchetti P
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):279-84. PubMed ID: 25267956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Prognostic Model Based on Circulating Tumour Cells is Useful for Identifying the Poorest Survival Outcome in Patients with Metastatic Colorectal Cancer.
    Chou WC; Wu MH; Chang PH; Hsu HC; Chang GJ; Huang WK; Wu CE; Hsieh JC
    Int J Biol Sci; 2018; 14(2):137-146. PubMed ID: 29483832
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review.
    Yang C; Zou K; Zheng L; Xiong B
    BMC Cancer; 2017 Nov; 17(1):725. PubMed ID: 29115932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and Therapeutic Significance of Circulating Tumor Cell Phenotype Detection Based on Epithelial-Mesenchymal Transition Markers in Early and Midstage Colorectal Cancer First-Line Chemotherapy.
    Lu G; Lu Z; Li C; Huang X; Luo Q
    Comput Math Methods Med; 2021; 2021():2294562. PubMed ID: 34777560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinico-pathological correlation of serial measurement of circulating tumor cells in 24 metastatic colorectal cancer patients receiving chemotherapy reveals interpatient heterogeneity correlated with CEA levels but independent of KRAS and BRAF mutation.
    Das A; Kunkel M; Joudeh J; Dicker DT; Scicchitano A; Allen JE; Sarwani N; Yang Z; Kaifi J; Zhu J; Liao J; El-Deiry WS
    Cancer Biol Ther; 2015; 16(5):709-13. PubMed ID: 25806877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and predictive value of circulating tumor cell analysis in colorectal cancer patients.
    de Albuquerque A; Kubisch I; Stölzel U; Ernst D; Boese-Landgraf J; Breier G; Stamminger G; Fersis N; Kaul S
    J Transl Med; 2012 Nov; 10():222. PubMed ID: 23146106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer.
    Aggarwal C; Meropol NJ; Punt CJ; Iannotti N; Saidman BH; Sabbath KD; Gabrail NY; Picus J; Morse MA; Mitchell E; Miller MC; Cohen SJ
    Ann Oncol; 2013 Feb; 24(2):420-428. PubMed ID: 23028040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
    Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
    Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
    Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
    Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
    Sastre J; Maestro ML; Gómez-España A; Rivera F; Valladares M; Massuti B; Benavides M; Gallén M; Marcuello E; Abad A; Arrivi A; Fernández-Martos C; González E; Tabernero JM; Vidaurreta M; Aranda E; Díaz-Rubio E
    Oncologist; 2012; 17(7):947-55. PubMed ID: 22643538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
    Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
    BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
    Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
    Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Role of Circulating Tumor Cell Trajectories in Metastatic Colorectal Cancer.
    Magri V; Marino L; Nicolazzo C; Gradilone A; De Renzi G; De Meo M; Gandini O; Sabatini A; Santini D; Cortesi E; Gazzaniga P
    Cells; 2023 Apr; 12(8):. PubMed ID: 37190081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The significant prognostic value of circulating tumor cells in colorectal cancer: A systematic review and meta-analysis.
    Tan Y; Wu H
    Curr Probl Cancer; 2018; 42(1):95-106. PubMed ID: 29277243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.